- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04464798
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas.
This Phase 1/2, multicenter, open-label study to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. Subjects must have received at least 2 prior lines of therapy, and have at least one measurable lesion according to Lugano 2014 classification.
Study will consist of two parts: Part 1 (Dose Escalation) which will be followed by Part 2 (Dose Expansion).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Creteil, France, 94010
- Local Institution - 203
-
Lillie Cedex, France, 59037
- Local Institution - 200
-
Montpellier CEDEX 5, France, 34295
- Local Institution - 201
-
Nantes cedex 1, France, 44093
- Local Institution - 202
-
Paris, France, 75010
- Local Institution - 204
-
Pessac, France, 33604
- Local Institution - 205
-
-
-
-
-
Berlin, Germany, 12203
- Local Institution - 401
-
Leipzig, Germany, 4103
- Local Institution - 402
-
Munster, Germany, 48149
- Local Institution - 403
-
Wuerzburg, Germany, 97080
- Local Institution - 404
-
-
-
-
-
Brescia, Italy, 25123
- Local Institution - 300
-
Milano, Italy, 20133
- Local Institution - 303
-
Pavia, Italy, 27100
- Local Institution - 301
-
Verona, Italy, 37134
- Local Institution - 302
-
-
-
-
-
Seoul, Korea, Republic of, 03722
- Local Institution - 502
-
Seoul, Korea, Republic of, 06351
- Local Institution - 501
-
Seoul, Korea, Republic of, 5505
- Local Institution - 500
-
-
-
-
-
Niaosong District Kaohsiung City, Taiwan, 83301
- Local Institution - 600
-
Taoyuan City, Taiwan, 33305
- Local Institution - 601
-
Taoyuan City, Taiwan, 40447
- Local Institution - 602
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Local Institution - 106
-
-
Florida
-
Lake Mary, Florida, United States, 32746
- Local Institution - 105
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Local Institution - 102
-
-
New York
-
New York, New York, United States, 10065
- Local Institution - 100
-
Rochester, New York, United States, 14642
- University of Rochester Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Local Institution - 103
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects must satisfy the following criteria to be enrolled in the study:
- Is ≥ 18 years of age at the time of signing the informed consent form (ICF).
Has histologically confirmed (per local evaluation) diagnosis of lymphoma according to 2016 World Health Organization (WHO) classification including:
- Cohort A: all subtypes including B-cell, T-cell and Natural killer (NK)-cell Non-Hodgkin lymphoma (NHL), and Classical Hodgkin lymphoma (cHL).
- Cohort B: all B-cell NHL.
- Cohort C: FL Grade 1-3a and MZL including extranodal marginal zone lymphoma (ENMZL) of mucosa-associated lymphoid tissue (MALT lymphoma), nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL)
- Cohort D: aggressive B-cell lymphoma and FL grade 1-3a
- Cohort E: aggressive B-cell lymphoma including DLBCL NOS, high-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements, Grade 3b FL and PMBCL
- Cohorts F and G: FL Grade 1 to 3a
Relapsed or refractory disease according to the following definitions:
- Aggressive B-cell lymphoma
- Follicular lymphoma (FL) and Marginal zone lymphoma (MZL): following at least 2 prior lines of systemic therapy (being previously exposed to at least 1 anti-CD20 mAb and 1 alkylating agent).
- Mantle cell lymphoma (MCL): following at least 2 prior lines of therapy including at least 1 immunochemotherapy and 1 bruton tyrosine kinase (BTK) inhibitor.
- Peripheral T-cell lymphoma (PTCL): following at least 2 prior lines of therapy OR after 1 prior line of standard therapy and being not eligible for any other approved regimen.
- Classical Hodgkin lymphoma (cHL): following at least 2 prior systemic lines of therapy and previously exposed to brentuximab vedotin and anti-PD1.
- All other subtypes: following at least 2 prior lines of therapy.
- Subjects previously treated with CAR-T therapy can be enrolled (irrespective of the indication).
- Subjects must not be eligible for any other approved treatment for their underlying lymphoma as assessed by the Investigator.
- Must have measurable disease defined by at least 1 fluorodeoxyglucose (FDG)-avid lesion for FDG-avid subtype and 1 bi-dimensionally measurable (> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification. Site of measurable disease cannot be previously irradiated.
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
Must have the following laboratory values:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L or ≥ 1.0 x 109/L
- Hemoglobin (Hb) ≥ 8 g/dL.
- Platelets (Plt) ≥ 75 x 109/L or ≥ 50 x 109/L
- Aspartate aminotransferase / serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase / serum glutamic pyruvic transaminase (ALT/SGPT) ≤ 2.5 x ULN.
- Serum total bilirubin ≤ 1.5 ULN except in cases of Gilbert's syndrome, then ≤ 3.0 ULN.
- Estimated serum creatinine clearance of ≥ 50 mL/min
All subjects must:
- Have an understanding that the study drug could have a potential teratogenic risk.
- Agree to follow all requirements defined in the Pregnancy Prevention Program for CC-220 Pregnancy Prevention Plan for Subjects in Clinical Trials.
Females of childbearing potential (FCBP1) must:
a. Have 2 negative pregnancy tests as verified by the Investigator prior to starting study treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment.
Male subjects must:
- Practice true abstinence2 or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study,
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
- Any significant medical condition, active infection (including severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2) suspected or confirmed, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
- Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
- Life expectancy ≤ 3 months.
- Diagnosis of lymphoblastic lymphoma.
- Aggressive lymphoma relapse requiring immediate cytoreductive therapy to avoid potential life-threatening consequences (eg, due to tumor location).
- Prior Grade 3 or 4 infusion related reaction with rituximab (for Cohorts B, E and F) or obinutuzumab (for Cohorts C and G).
- Prior therapy with the cereblon-modulating drug CC-99282.
- Chronic systemic immunosuppressive therapy or corticosteroids.
- Prior ASCT ≤ 3 months prior to starting CC-220 or > 3 months AND with unresolved, Grade > 1, treatment-related toxicity.
- Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-220 or > 6 months with unresolved, Grade > 1, treatment-related toxicity.
- Hypersensitivity to the active substance or to murine proteins, or to any of the other excipients of rituximab or obinutuzumab.
- Known allergy to thalidomide, pomalidomide or lenalidomide.
- Inability or unwilling to undergo protocol required thromboembolism prophylaxis.
- Major surgery ≤ 2 weeks prior to starting CC-220;
- Peripheral neuropathy ≥ Grade 2 (NCI CTCAE v5.0).
- Documented or suspected central nervous system (CNS) involvement of disease.
- Subject with clinically significant cardiac disease.
- Known seropositivity for or active viral infection with human immunodeficiency virus (HIV).
- Known chronic active hepatitis B
History of other malignancy, unless the subject has been free of the disease for ≥ 3 years; exceptions to the ≥ 3-year time limit include history of the following:
- Incidental histologic finding of prostate cancer (or prostate cancer that has been treated with curative intent
Other protocol defined inclusion/exclusion criteria could apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A- Monotherapy in R/R lymphoma subjects
Subjects with Relapsed or Refractory (R/R) lymphoma who have been allocated to Cohort A will receive CC-220 monotherapy (MonoT).
Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles.
|
Oral
Other Names:
|
Experimental: Cohort B- CC-220 and rituximab in R/R B-Cell NHL subjects
Subjects with R/R B-cell Non Hodgkin Lymphoma (NHL) who have been allocated to Cohort B will receive CC-220 in combination with rituximab.
|
Oral
Other Names:
SC and IV infusion
|
Experimental: Cohort C - CC-220 and obinutuzumab in R/R FL or MZL subjects
Subjects with R/R FL (Grade 1 to 3a) or MZL who have been allocated to Cohort C will receive CC-220 in combination with obinutuzumab.
|
Oral
Other Names:
IV Infusion
|
Experimental: Cohort D -CC-220 monotherapy in participants with aggressive B-cell lymphoma and follicular lymphoma
|
Oral
Other Names:
|
Experimental: Cohort E - CC-220 and rituximab in participants with aggressive B-cell lymphoma
|
Oral
Other Names:
SC and IV infusion
|
Experimental: Cohort F - CC-220 and rituximab with follicular lymphoma grade 1-3a
|
Oral
Other Names:
SC and IV infusion
|
Experimental: Cohort G - CC-220 plus obinutuzumab in participants with follicular lymphoma grade 1-3a
|
Oral
Other Names:
IV Infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD)
Time Frame: During the First cycle (each cycle is 28 days)
|
is defined as the dose that satisfies the escalation with overdose control (EWOC) criterion that the posterior probability to have excessive toxicity is less than 25% and has the highest probability of dose-limiting toxicity (DLT) rate being in the target interval (0.16 to 0.33)
|
During the First cycle (each cycle is 28 days)
|
Recommended Phase 2 Dose (RP2D)
Time Frame: During the first Cycle (each cycle is 28 days)
|
is defined as the dose that will be selected for dose expansion based on PK/Pd and MTD
|
During the first Cycle (each cycle is 28 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events (AEs)
Time Frame: From first dose to 28 days after last subject discontinues study treatment
|
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study.
It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology.
Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.
|
From first dose to 28 days after last subject discontinues study treatment
|
Pharmacokinetics - Cmax
Time Frame: At Cycle1 Day15 and Cycle2 Day15 (each cycle is 28 days)
|
Maximum plasma concentration
|
At Cycle1 Day15 and Cycle2 Day15 (each cycle is 28 days)
|
Pharmacokinetics - Ctrough
Time Frame: At Cycle1 Day15 and Cycle2 Day15 (each cycle is 28 days)
|
Observed plasma concentration at the end of the dosing interval
|
At Cycle1 Day15 and Cycle2 Day15 (each cycle is 28 days)
|
Pharmacokinetics - AUC(TAU)
Time Frame: At Cycle1 Day15 and Cycle2 Day15 (each cycle is 28 days)
|
Area under the plasma concentration-time curve from time zero to tau, where tau is the dosing interval
|
At Cycle1 Day15 and Cycle2 Day15 (each cycle is 28 days)
|
Pharmacokinetics - tmax
Time Frame: At Cycle1 Day15 and Cycle2 Day15 (each cycle is 28 days)
|
Time to maximum plasma concentration
|
At Cycle1 Day15 and Cycle2 Day15 (each cycle is 28 days)
|
Pharmacokinetics - CLT/F
Time Frame: At Cycle1 Day15 and Cycle2 Day15 (each cycle is 28 days)
|
Apparent total plasma clearance
|
At Cycle1 Day15 and Cycle2 Day15 (each cycle is 28 days)
|
Best Overall Response Rate (ORR)
Time Frame: Approximately 5 years
|
is defined as the proportion of subjects with best overall response as either CR or partial response (PR) before subsequent anti-lymphoma therapy
|
Approximately 5 years
|
Complete Response Rate (CRR)
Time Frame: Approximately 5 years
|
is defined as the proportion of subjects experiencing CR before receiving any subsequent anti-lymphoma therapy
|
Approximately 5 years
|
Time to Response (TTR)
Time Frame: Approximately 5 years
|
is defined as the time from enrollment dose date to the date of first documented response (≥ PR)
|
Approximately 5 years
|
Duration of Response (DOR)
Time Frame: Approximately 5 years
|
is defined as the time from first dose date to the date of first documented response (≥ PR)
|
Approximately 5 years
|
Progression-free Survival (PFS)
Time Frame: Approximately 5 years
|
is defined as the time from enrollment date to the first occurrence of disease progression or death from any cause
|
Approximately 5 years
|
Overall Survival (OS)
Time Frame: Approximately 5 years
|
is defined as the time from enrollment date to death from any cause
|
Approximately 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
- Obinutuzumab
Other Study ID Numbers
- CC-220-NHL-001
- U1111-1254-1772 (Registry Identifier: WHO)
- 2020-000354-10 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Information relating to our policy on data sharing and the process for requesting data can be found at the following link:
https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
Clinical Trials on CC-220
-
CelgeneCompleted
-
CelgeneCompleted
-
CelgeneCompletedHealthy Volunteers | Hepatic ImpairmentUnited States
-
CelgeneCompleted
-
CelgeneCompletedSystemic Lupus ErythematosusUnited States
-
CelgeneCompletedLupus Erythematosus, SystemicUnited States, Belgium, Germany, Spain, Canada, Serbia, Colombia, Poland, Argentina, Brazil, Mexico, Hungary, France, Russian Federation, Italy
-
Celgene CorporationCompleted
-
Bristol-Myers SquibbCelgeneCompleted
-
CelgeneCompleted